PRESS-RELEASE filed Nov 3, 2026 at 16:01 ET
Spyre Therapeutics reported Q3 2026 net loss of $96.1M ($0.94 per common share), wider than the $11.2M loss a year ago, driven by increased R&D spending. The company highlighted positive Phase 2 data for its IBD pipeline and plans to advance TL1A programs into pivotal HS studies, with $1.47B pro forma cash providing runway into H2 2029. The EPS of -$0.94 is below the consensus estimate of -$0.84, representing a miss.